Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Bartomeu Massutí-Sureda"'
Autor:
Amparo Burgos-San José, Claudia Colomer-Aguilar, Daniel Martínez-Caballero, Bartomeu Massutí-Sureda
Publikováno v:
Farmacia Hospitalaria, Vol 45, Iss 03, Pp 121-125 (2021)
Objective: To determine the effectiveness and safety of atezolizumab, nivolumab and pembrolizumab in patients with non-small cell lung cancer.Method: This is a retrospective observational study including patients treated in second line and beyond. Th
Externí odkaz:
https://doaj.org/article/cfc4f0c3dca247c9b056a453996a1c49
Autor:
Eloisa Jantus-Lewintre, Bartomeu Massutí Sureda, José Luis González Larriba, Delvys Rodríguez-Abreu, Oscar Juan, Ana Blasco, Manuel Dómine, Mariano Provencio Pulla, Javier Garde, Rosa Álvarez, Inmaculada Maestu, Ramón Pérez de Carrión, Ángel Artal, Christian Rolfo, Javier de Castro, Mónica Guillot, Juana Oramas, Ramón de las Peñas, Lioba Ferrera, Natividad Martínez, Òlbia Serra, Rafael Rosell, Carlos Camps
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Finding angiogenic prognostic markers in advanced non-small-cell lung cancer is still an unmet medical need. We explored a set of genetic variants in the VEGF-pathway as potential biomarkers to predict clinical outcomes of patients with non-small-cel
Externí odkaz:
https://doaj.org/article/53c890df8ad048b5aa884049551e96df
Autor:
Bartomeu Massutí Sureda, Allan C. Halpern, Joachim von Pawel, Leonard B. Saltz, Jean Pierre Delord, Jennifer S. Temel, James G. Krueger, Roman Perez-Soler, Denis Soulières, James J. Leyden, Karen Kelly, Salvatore Siena
Publikováno v:
The Oncologist. 10:345-356
Learning Objectives After completing this course, the reader will be able to: Describe the clinical and pathological characteristics of the cutaneous rash secondary to anti-EGFR therapy.Explain the prognostic implications of the cutaneous rash second
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4fe7c53cbba1484192413939c42718a4
https://doi.org/10.1634/theoncologist.10-5-345
https://doi.org/10.1634/theoncologist.10-5-345